Background/Aim: The KIAA1199 gene has been associated with cancer-cell proliferation, but its functions remain poorly studied. Here, we examined the clinical significance of the KIAA1199 mRNA levels in locally advanced gastric cancer (GC). Materials and Methods/Results: Using samples from 254 patients with stage II/III GC, we found significantly higher KIAA1199 levels in cancerous tissues compared to adjacent normal mucosa (ANM). There was no significant relationship between KIAA1199 expression and clinical features. Although overall survival rates (OSR) of patients, who underwent surgery did not correlate with KIAA1199 expression, patients who underwent adjuvant chemotherapy with S-1 and had high KIAA1199 levels displayed significantly lower OSR. KIAA1199 knock down (KIAA1199-KD) suppressed proliferation, invasiveness, and sensitivity of GC cells to 5-fluorouracil (5-FU). Conclusion: KIAA1199 expression appears to be a promising prognostic marker in patients with locally advanced GC, who underwent postoperative adjuvant chemotherapy with S-1. KIAA1199 may represent a novel target for GC pharmacotherapy.Gastric cancer (GC) is the fifth most common cancer type (1,033,701 affected individuals in 2018) and accounts for the third highest number of cancer-related deaths (781,631 death cases in 2018) (1). In Japan, postoperative adjuvant S-1 chemotherapy is one of the standard treatments for locally advanced GC after radical resection (2-4). Fluorinatedpyrimidine is still the key drug for postoperative adjuvant chemotherapy against GC (5-7). However, such GC treatments are not sufficiently efficient (3,6). Personalized postoperative adjuvant chemotherapy using biomarkers is a promising treatment strategy for improving outcomes of patients with locally advanced GC.The KIAA1199 gene was discovered as an inner-earspecific gene encoding the KIAA1199 protein (8). KIAA1199 is located at chromosome band 15q25.1, the same region where the brain tumor-suppressor gene was mapped (9-11). Recent studies have reported that KIAA1199 repression attenuates Wnt/β-catenin signaling and decreases the proliferation of colorectal cancer cells (12). Furthermore, our DNA microarray analysis showed a 10-fold increase in KIAA1199 expression in GC tissue compared to adjacent normal mucosa (ANM). Here, we examined the clinical significance of KIAA1199 expression in locally advanced GC and its potential as a new target for anti-GC agents. Materials and MethodsPatients and samples. The examined surgical samples of cancerous tissue and paired ANM were obtained from 254 patients with previously untreated stage II/III GC, who underwent radical 6567

No abstract

Reports of recurrence after obturator hernia repair are few. We describe the case of an 89‐year‐old woman who presented to us with a thrice recurrent obturator hernia. She had undergone open non‐mesh repair twice and then laparoscopic non‐mesh repair. She was readmitted to our hospital 6 months after the laparoscopic repair. Manual reduction was successful, paving the way for elective transabdominal preperitoneal repair. During the endoscopic repair, surgical mesh was placed extraperitoneally over the hernia defect and then fixed to Cooper's ligament with absorbable tacks. The patient was discharged on postoperative day 2 without complications. In the 2 months that have passed since the surgery there has been no sign of recurrence, but the patient will be carefully followed up. Repair of a recurrent obturator hernia is technically challenging; however, the transabdominal preperitoneal approach seems to be reliable and safe.

No abstract